BioTrinity 2024 was deemed a “funding winter” for life science SMEs. In 2023, biotech funding dropped by 43.2% compared to 2022. This made investors more cautious and pushed them to prioritise existing portfolios. Access the most comprehensive Company Profiles on the market.